Original Research J Clin Psychiatry December 2025

Obstetric Outcomes With Second-Generation Long-Acting Injectable Versus Oral Antipsychotics

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. Clinical Summary Pregnant patients with schizophrenia or bipolar disorder often need ongoing antipsychotic treatment, and relapse risk from undertreatment can be clinically serious for both mother and fetus. Clinicians have more safety data for oral antipsychotics than for long-acting injectable antipsychotics, so this comparison directly informs whether formulation choice changes obstetric risk. FAQ Do long-acting injectable antipsychotics increase obstetric complications in pregnancy compared with oral second-generation antipsychotics? 9 questions
Key Takeaways This comparison was strengthened by propensity score matching on 26 features, producing 2 cohorts of 2,025 patients with all covariates balanced at SMDs below 0.1 and a maximum standardized difference of 0.095. 6 takeaways Clinical Guide How should clinicians choose between second-generation long-acting injectable and oral antipsychotics for a pregnant patient with serious mental illness? 8 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe